Oppenheimer Asset Management Inc. Puma Biotechnology, Inc. Transaction History

Oppenheimer Asset Management Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$2.85 - $6.58 $84,972 - $196,182	-29,815 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.63 - $9.39 $11,337 - $16,056	1,710 Added 6.08%	29,815 $209,000
Q2 2021 Aug 03, 2021	SELL	$8.98 - $11.6 $93,787 - $121,150	-10,444 Reduced 27.09%	28,105 $258,000
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $7,513 - $10,917	801 Added 2.12%	38,549 $375,000
Q4 2020 Feb 11, 2021	BUY	$7.78 - $12.13 $6,978 - $10,880	897 Added 2.43%	37,748 $387,000
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $105,279 - $123,453	11,082 Added 43.01%	36,851 $372,000
Q2 2020 Aug 11, 2020	BUY	$7.01 - $13.24 $61,365 - $115,902	8,754 Added 51.45%	25,769 $269,000
Q1 2020 May 08, 2020	BUY	$6.28 - $14.57 $44,650 - $103,592	7,110 Added 71.78%	17,015 $144,000
Q4 2019 Feb 07, 2020	BUY	$6.5 - $10.73 $2,496 - $4,120	384 Added 4.03%	9,905 $87,000
Q3 2019 Oct 31, 2019	BUY	$8.75 - $12.85 $23,948 - $35,170	2,737 Added 40.34%	9,521 $102,000
Q2 2019 Aug 09, 2019	BUY	$12.3 - $35.76 $3,776 - $10,978	307 Added 4.74%	6,784 $86,000
Q1 2019 Apr 24, 2019	BUY	$20.77 - $42.37 $30,199 - $61,605	1,454 Added 28.95%	6,477 $251,000
Q4 2018 Jan 30, 2019	BUY	$20.07 - $46.7 $7,365 - $17,138	367 Added 7.88%	5,023 $102,000
Q3 2018 Oct 26, 2018	BUY	$41.2 - $59.85 $191,827 - $278,661	4,656 New	4,656 $213,000
Q4 2017 Feb 07, 2018	SELL	$93.85 - $132.45 $22,617 - $31,920	-241 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $17,352 - $28,859	241	241 $29,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $139M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.